期刊文献+

塞来昔布联合p65miRNA抑制人乳腺癌移植瘤的生长 被引量:1

Effects of celecoxib combined with p65miRNA on tumor growth in breast cancer xenografts in nude mice
下载PDF
导出
摘要 目的探讨下调核因子NF-κB p65亚基的表达联合塞来昔布对人乳腺癌裸鼠移植瘤生长的协同抑制效应及其机制。方法建立人乳腺癌裸鼠移植瘤模型,随机将裸鼠分为6组,control组、Neg-miRNA组、p65miRNA组、塞来昔布组、塞来昔布+Neg-miRNA组、塞来昔布+p65miRNA组。观察治疗前后裸鼠的一般状态、肿瘤体积和瘤重,计算平均抑瘤率。免疫组化法检测p65miRNA干扰后肿瘤组织中p65蛋白的表达。RT-PCR、Western印迹法检测肿瘤组织中血管内皮生长因子(VEGF)、金属基质蛋白酶(MMP-2)基因mRNA及蛋白表达的变化。结果塞来昔布组、p65miRNA组和塞来昔布+p65miRNA组肿瘤生长受到明显抑制,抑瘤率分别为43.23%、40.72%及61.69%。p65miRNA组较对照组p65蛋白表达明显减少。塞来昔布组、p65miRNA组和塞来昔布+p65miRNA组VEGF、MMP-2 mRNA及蛋白表达受到不同程度地抑制。结论塞来昔布及p65miRNA均具有明显的抗肿瘤作用,联合应用时具有一定的协同作用,可显著抑制人乳腺癌裸鼠移植瘤的生长,并可显著下调VEGF、MMP-2的表达。 Objective To evaluate the effects of celecoxib combined with p65miRNA on tumor growth in breast cancer xenografts in nude mice and its mechanism.Methods After successfully establishing breast cancer xenografts in nude mice,the mice were randomly divided into control,the neg-miRNA,the p65 miRNA,the celecoxib,the celecoxib combined with neg-miRNA and the celecoxib combined with p65miRNA groups.On the 42nd day after treatment,tumor volume,weight and the rate of tumor inhibition were measured.Tumor tissues were collected and assessed for the detection of p65,VEGF and MMP-2 by immunohistochemistry,Western blotting and RT-PCR.Results The rate of tumor inhibition was 43.23% in the celecoxib group,40.72% in the p65miRNA group and 61.69% in the celecoxib combined with p65miRNA group.Immunohistochemical results showed a significant decrease in p65 expression of the p65miRNA group.Western blotting and RT-PCR analysis showed that the expressions of VEGF and MMP-2 were significantly reduced in the celecoxib,the p65miRNA and the celecoxib combined with p65miRNA groups.Conclusions The combination of celecoxib and p65miRNA can enhance the anti-tumor effect in human breast cancer xenografts,by down-regulating expressions of VEGF and MMP-2.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第9期1853-1856,共4页 Chinese Journal of Gerontology
基金 河北省科学技术研究与发展计划项目(No.10276167)
关键词 乳腺癌 塞来昔布 NF-ΚBP65 MIRNA Breast cancer Celecoxib NF-κB p65 miRNA
  • 相关文献

参考文献9

  • 1Agrawal A,Fentiman IS.NSAIDs and breast cancer:a possible prevention and treatment strategy(J).Int J Clin Pract,2008;62(3):444-9.
  • 2王玲,单保恩,张建彬.塞来昔布对人三阴性乳腺癌细胞MDA-MB-231迁移、侵袭及黏附性的影响[J].中国癌症杂志,2011,21(4):266-271. 被引量:15
  • 3王玲,刘丽宏,单保恩,张超,桑梅香,李嘉.Celecoxib下调NF-кB信号通路促进人乳腺癌MDA-MB-231细胞凋亡的体外研究[J].癌症,2009,28(6):569-574. 被引量:20
  • 4Ashok V,Dash C,Rohan TE,et al.Selective cyclooxygenase-2(COX-2)inhibitors and breast cancer risk(J).Breast,2011;20(1):66-70.
  • 5Falandry C,Canney PA,Freyer G,et al.Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer(J).Ann Oncol,2009;20(4):615-20.
  • 6Chaturvedi MM,Sung B,Yadav VR,et al.NF-κB addiction and its role in cancer:'one size does not fit all'(J).Oncogene,2011;30(14):1615-30.
  • 7Valovka T,Hottiger MO.p65 controls NF-κB activity by regulating cellu-lar localization of IκBβ(J).Biochem J,2011;434(2):253-63.
  • 8Van der Meel R,Symons MH,Kudernatsch R,et al.The VEGF/Rho GT-Pase signalling pathway:a promising target for anti-angiogenic/anti-inva-sion therapy(J).Drug Discov Today,2011;16(5-6):219-28.
  • 9Bourboulia D,Stetler-Stevenson WG.Matrix metalloproteinases(MMPs)and tissue inhibitors of metalloproteinases(TIMPs):positive and negative regulators in tumor cell adhesion(J).Semin Cancer Biol,2010;20(3):161-8.

二级参考文献24

  • 1吴高松,易继林,邸方,邹声泉,李兴睿.Celecoxib Inhibits Proliferation and Induces Apoptosis via Cyclooxygenase-2 Pathway in Human Pancreatic Carcinoma Cells[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2005,25(1):42-44. 被引量:4
  • 2Jiongyu Chen,Yonggang Ran,Chaoqun Hong,Zhijian Chen,Yanjie You.Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein[J]. Cytotechnology . 2010 (5)
  • 3Dawood S.Triple-negative breast cancer:epidemiology and management options. Drugs . 2010
  • 4Foulkes WD,Smith IE,Reis-Filho JS.Triple-negative breast cancer. The New England Journal of Medicine . 2010
  • 5Gao J,Jia WD,Li JS,et al.Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice. Journal of International Medical Research . 2010
  • 6Park SW,Kim HS,Hah JW,et al.Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anti Cancer Drugs . 2010
  • 7Hurvitz SA,Finn RS.What’’s positive about’’triple-negative’’breast cancer. Future Oncol . 2009
  • 8Caldas-Lopes E,Cerchietti L,Ahn JH,et al.Hsp90 inhibitor PU-H71,a multimodal inhibitor of malignancy,induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America . 2009
  • 9Myriam Pokette,Philippe Birembaut.Membrane-type metalloproteinases in tumor invasion. The International Journal of Biochemistry and Cell Biology . 1998
  • 10Ohbayashi H.Matrix metalloproteinases in lung diseases. Current Protein and Peptide Science . 2002

共引文献31

同被引文献14

  • 1Tokiniwa H.Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer[J].Breast Cancer,2011,19(4):309-314.
  • 2Ohsawa M,Ikura Y,Fukushima H,et al.Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma[J].Oncology,2005,68(4/6):422-431.
  • 3Lu D,Shi HC,Wang ZX,et al.Multidrug resistanceassociated biomarkers PGP,GST-pi,Topo-Ⅱ and LRP as prognostic factors in primary ovarian carcinoma[J].Br J Biomed Sci,2011,68(2):69-74.
  • 4Crea F,Duhagon Serrat MA,Hurt EM,et al.BMIl silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer[J].Int J Cancer,2011,128(8):1946-1954.
  • 5Lu D,Shi HC,Wang ZX,et al.Multidrug resistanceassociated biomarkers PGP,GST-pi,Topo-II and LRP as prognostic factors in primary ovarian carcinoma[J].Br J Biomed Sci,2011,68(2):69-74.
  • 6Zhu WY,Hunag YY,Liu XG,et al.Prognostic evaluation of CapG,Gelsolin,P-gp,GSTPl,and Topo-II proteins in non-small cell lung cancer[J].Anat Rec,2012,295(2):208-214.
  • 7Zhu D,Wan X,Huang H,et al.Knockdown of Bmil inhibits the sternness properties and tumorigenicity of human bladder cancer stem cell-like side population cells[J].Oncol Rep,2014,31(2):727-736.
  • 8王轶楠,李红民,马守东,赵郁,刘卫东,岳海书.P-gp170、GST-π、TOPOⅡ在外周T细胞淋巴瘤中的表达及意义[J].现代肿瘤医学,2009,17(8):1543-1546. 被引量:4
  • 9邓晓斌,王珊,邹琳,李长春,章均,欧阳军.小儿恶性肿瘤化疗前后外周血多药耐药基因、多药耐药相关蛋白基因、肺耐药蛋白基因的变化及临床意义[J].第三军医大学学报,2010,32(10):1087-1090. 被引量:7
  • 10袁凯,付荣湛,孙勇.P-糖蛋白和肺耐药蛋白在浸润性乳腺癌中的表达及其临床意义[J].中华乳腺病杂志(电子版),2010,4(4):31-34. 被引量:6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部